BOSTON, April 24, 2024 Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells,.
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
BOSTON, April 08, 2024 Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today.
Overall response rate of 47% and disease control rate of 65% in first line recurrent/metastatic HNSCC patients treated with CUE-101 and KEYTRUDA® ORR of 56% in patients with low expression of.